Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.


  ONCOgenic GPCR Network of Excellence and Training




Early stage researcher 2 (ESR2) project

Supervision: Dr. Raimond Heukers, Dr. Edward Dolk

Host: QVQ Holding BV


I- Project proposal:


  1. The development and characterization of multivalent anti-CXCR4/ACKR3/RTK nanobody constructs to modulate CXCR4/ACKR3 oligomers.
  2. Use multivalent Nbs for imaging of CXCR4/ACKR3 using site-directionally conjugated nanobodies



Nanobody constructs will be generated through genetic fusion, cloning and production in E.coli or S.cerevisiae. Produced nanobody constructs will be purified using affinity chromatography and gel filtration. Generated molecules will be assessed for production yields, integrity and functionality/potency in close collaboration with the VU University Amsterdam and University of Nottingham. This will involve a wide range of established techniques (UV-VIS spectrometry, SDS-PAGE, ELISA, ligand displacement and reporter gene assays and bioluminescence resonance energy transfer (BRET)). In addition, generated nanobody constructs will be turned into imaging agents via directional conjugation, which will be tested for imaging receptor complexes by using modalities.


Planned secondments:

Vrije Universiteit Amsterdam (Smit lab)

University of Nottingham (Hill lab)


II - Requirement candidate:

Required diploma: MSc in biology, chemistry, biochemistry, microbiology or molecular-, biomedical-, pharmaceutical- or related life sciences.

Required expertise: biochemistry and molecular biology (DNA and protein level).

Recommended expertise: molecular cloning, phage-display, protein production and purification, affinity chromatography, FPLC, (yeast) fermentation, site-directed conjugations, SDS-PAGE, ELISA, FACS, cell culture, cell based assays, fluorescence microscopy and working experience in industry.


Key publications:

  1. Van Hout A, Klarenbeek A, Bobkov V, Doijen J, Arimont M, Zhao C, Heukers R, Rimkunas R, de Graaf C, Verrips T, van der Woning B, de Haard H, Rucker JB, Vermeire K, Handel T, Van Loy T, Smit MJ, Schols D. 2018. CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry.Biochem Pharmacol. 2018 Oct 17. pii: S0006-2952(18)30436-2.
  2. Bobkov V, Zarca AM, Van Hout A, Arimont M, Doijen J, Bialkowska M, Toffoli E, Klarenbeek A, van der Woning B, van der Vliet HJ, Van Loy T, de Haard H, Schols D, Heukers R, Smit MJ. 2018. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions. Biochem Pharmacol. 2018 Oct 17. pii: S0006-2952(18)30435-0.
  3. Klarenbeek A, El Mazouari K, Desmyter A, Blanchetot C, Hultberg A, de Jonge N, Roovers RC, Cambillau C, Spinelli S, Del-Favero J, Verrips T, de Haard HJ, Achour I. 2015. Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform. MAbs. 7(4):693-706. doi: 10.1080/19420862.2015.1046648.
  4. Gorlani A, de Haard H, Verrips T. 2012. Expression of VHHs in Saccharomyces cerevisiae. Methods Mol Biol. 911:277-86.
  5. Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W, Saunders M, De Haard HJ, Schols D, Leurs R, Vanlandschoot P, Verrips T, Smit MJ. 2010. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A. 23;107(47):20565-70.


For more information:

Dr. Raimond Heukers - This email address is being protected from spambots. You need JavaScript enabled to view it. or 



Apply here


Contact details

Please contact us at:

ONCORNET Coordinator
VU University Amsterdam
The Netherlands

Funded by

marie curie actions   Marie Curie Actions



EU Horizon 2020



european union logo   European Union